Jubilant Pharmova Ltd
Jubilant Pharmova Q1 FY25 earnings call: Revenue & Margins
Q1 FY25 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹1,732Cr
- +9.1% YoY
- Net profit
- ₹482Cr
- +7933.3% YoY
- Margin
- 15%
- +4 pp YoY
Guidance rank: #70 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Jubilant Pharmova Ltd Q1 FY25 key numbers
- Revenue
- Total Income for Q1’FY25 was Rs. 1,746 Cr, a 9% increase YoY.
As stated in Jubilant Pharmova Ltd's Q1 FY25 investor presentation · published 24 Sept 2026. Reported figures, not investment advice.
Based on Jubilant Pharmova Ltd's Q1 FY25 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Total Income for Q1’FY25 was Rs. 1,746 Cr, a 9% increase YoY. EBITDA: Rs. 266 Cr. in Q1’FY25, up 50% YoY.
From Jubilant Pharmova Ltd's Q1 FY25 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Total Income for Q1’FY25 was Rs. 1,746 Cr, a 9% increase YoY.
- Segment revenues (Q1’FY25, YoY % increase):
- Radiopharma: Rs. 832 Cr (up from Rs. 691 Cr)
- Radiopharmaceuticals: Rs. 262 Cr (+28%)
- Radiopharmacies: Rs. 570 Cr (+17%)
- Allergy Immunotherapy: Rs. 168 Cr (+11%)
- CDMO Sterile Injectables: Rs. 324 Cr (+27%)
- Generics: Rs. 156 Cr (down 23%)
- CRDMO: Rs. 243 Cr (down YoY from Rs. 280 Cr)
- Volume and price increases primarily drove growth in Radiopharma and Allergy Immunotherapy.
- Outlook:
- Expect continued revenue growth momentum in FY25.
- CDMO Sterile Injectables Line 3 & 4 production to start in FY26 and FY28 with revenue potential of USD 160-180 million.
- New product launches planned (6-8 annually) in US and other international markets.
2 more points from Jubilant Pharmova Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Jubilant Pharmova Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Spokane Sterile Injectables Expansion:
- Doubling capacity with state-of-the-art technology.
- Total investment: USD 285 million, partly funded (USD 149.6 million) by US Govt.
- Line 3 commercial production expected FY26; Line 4 in FY28.
- Revenue potential for Lines 3 & 4 combined: USD 160-180 million.
- Efforts underway to fill new capacity faster than industry average (3-4 years).
- Radiopharmacy Network Expansion:
- Planned investment: USD 50 million.
- Expand PET radiopharmacy network to 9 sites; total network to 52 sites in US.
- Fully operational by FY28 with expected RoCE >20%.
- Roorkee Solid Dosage Facility:
- Facility status changed from Salisbury, Maryland to Roorkee.
- Exports to US expected to increase gradually; supply to US market to start H2’FY25.
2 more points from Jubilant Pharmova Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Jubilant Pharmova Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Jubilant Pharmova Ltd said on order book & pipeline — free account, 30 seconds.
Jubilant Pharmova Ltd — Quarterly revenue & net profit
Jubilant Pharmova Ltd Q1 FY25 results — key figures
| ₹ Cr | Q1 FY25 | Q1 FY24 | YoY | Q4 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue | 1,732 | 1,587 | +9.1% | 1,759 | -1.5% |
| Operating profit (EBITDA) | 252 | 168 | +50% | 271 | -7% |
| Operating margin | 15% | 11% | +4 pp | 15% | 0 pp |
| Profit before tax | 500 | 25 | +1900% | -54 | — |
| Net profit (PAT) | 482 | 6 | +7933.3% | -62 | — |
| EPS (₹) | 30.26 | 0.40 | +7465% | -3.68 | — |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹2.3K Cr, net profit ₹119 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Jubilant Pharmo's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- NGL Fine Chem (Q1 FY25)
Q1 FY25 revenue from operations: ₹90.75 crores, up 27.75% year-on-year (YoY) from ₹71.04 crores in Q1 FY24 (Page 8). Key concall takeaways from NGL Fine Chem…
- Shree Ganesh Rem (Q1 FY25)
Q1FY25 Revenue from Operations: ₹24.78 crore, down 8% YoY from Q1FY24's ₹26.84 crore. Key concall takeaways from Shree Ganesh Remedies Ltd's Q1 FY25 earnings…
- Themis Medicare (Q1 FY25)
122.99 Cr, up 27.26% YoY from Rs. Key concall takeaways from Themis Medicare Ltd's Q1 FY25 earnings call — and how it ranks against sector peers.
- Fermenta Biotech (Q1 FY25)
Q1-FY25 consolidated operational revenue: INR 781 million, down 5.3% YoY (Q1-FY24: INR 824 million). Key concall takeaways from Fermenta Biotech Ltd's Q1 FY25…
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Jubilant Pharmova Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Jubilant Pharmova Ltd Q1 FY25 results?
Total Income for Q1’FY25 was Rs. 1,746 Cr, a 9% increase YoY. EBITDA: Rs. 266 Cr. in Q1’FY25, up 50% YoY.
What is Jubilant Pharmova Ltd share price analysis?
Jubilant Pharmova Ltd currently shows a neutral. The stock trades at a P/E of 43.7 with a market cap of ₹16,972 Cr. Investors should review the full earnings analysis for detailed insights.
Is Jubilant Pharmova Ltd planning capital expenditure?
Spokane Sterile Injectables Expansion: - Doubling capacity with state-of-the-art technology.
Keep Jubilant Pharmova Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.